RANI250117P2500
- 1.30
- -0.02-1.52%
Rani Therapeutics Newsroom
H.C. Wainwright Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $9
Rani Therapeutics Hldgs Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Immutep Ltd (OtherPRRUF)
Maxim Group Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $15
Maxim Group Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $15
Oppenheimer Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $17
Analysts Are Bullish on These Healthcare Stocks: Avadel Pharmaceuticals (AVDL), Rani Therapeutics Holdings (RANI)
Rani Therapeutics Hldgs Analyst Ratings
H.C. Wainwright Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $9
Buy Rating Affirmed for Rani Therapeutics: Promising Developments in Oral Obesity Treatment With RaniPill
Rani Therapeutics Hldgs Analyst Ratings
HC Wainwright & Co. Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $9
Analysts Offer Insights on Healthcare Companies: Hoth Therapeutics (HOTH), Rewalk Robotics (LFWD) and Rani Therapeutics Holdings (RANI)
H.C. Wainwright Maintains Rani Therapeutics(RANI.US) With Buy Rating, Cuts Target Price to $9
CCORF Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $9
Analysts Conflicted on These Healthcare Names: Merus (MRUS), Staar Surgical (STAA) and Rani Therapeutics Holdings (RANI)
Innovative Oral Delivery Platform Drives Buy Rating for Rani Therapeutics Holdings
Analysts Offer Insights on Healthcare Companies: Lumos Pharma (LUMO) and Rani Therapeutics Holdings (RANI)
Rani Therapeutics Hldgs Analyst Ratings
Rani Therapeutics Hldgs Analyst Ratings